Mythic Therapeutics, Inc.

Meet Malina Traianova, our Director, Clinical Laboratory and Vendor Management. Malina is at the forefront of Mythic's clinical program, acting as a vital link between our clinical sites and the?company as she ensures patient samples?and data?are collected and handled?with?great?care.?We are so grateful for the critical work Malina is doing to ensure the success of our MYTX-011 Phase 1 clinical program.?? ? Below, Malina shares what makes working at Mythic so special:? ? #MeetMythic?

We’re?honored and humbled?to be a 2024 BostInno #FireAwards honoree in recognition?of our efforts to deliver next-generation?of #ADCs with the potential to expand this promising class of targeted cancer therapies to more patients. ? Looking forward to celebrating alongside our fellow innovators in Boston’s #startup ecosystem. View the full list of honorees here:?https://lnkd.in/eCw7utud. #lifesciences

Our?#FateControl??technology?creates?the next generation of #ADCs?that strive to deliver greater efficacy with fewer of the tolerability challenges of chemotherapy, and expand the?population of patients who might benefit from this important class of targeted therapy. ? Our CEO,?George Eliades, shares with?Danielle Golovin, Ph.D.,?how we’re paving the way for breakthroughs in #cancer treatment?with our cMET targeting ADC, MYTX-01 - designed to overcome the?“efficacy?bottleneck”?of low?target?expression by?increasing?internalization in cancer cells, while decreasing uptake in?healthy?cells. ? Learn more about our story and the broader #ADC landscape in?BioCentury Inc.:?https://lnkd.in/ezfdh-SZ.

In the latest episode of Healio’s Oncology Overdrive podcast, our Co-founder and Chief Scientific Officer, Brian Fiske, Ph.D.,?joined Shikha Jain, MD, FACP to discuss entrepreneurship in #biotech, #ADC developments and more. Tune in to learn how his career through biotech has helped shape his current role at Mythic as we strive to develop better ADCs for patients everywhere.? ? Listen here: https://bit.ly/4eqUvEs? ? Healio | HemOnc Today ?

Meet Deepak Kanojia, Ph.D., our Principal Scientist, In Vivo Pharmacology. In this pivotal role, Dr. Kanojia leads the design and execution of the in vivo studies that are integral to translating our early-stage discoveries into viable treatment options. His work is crucial in our mission to bringing impactful and innovative #ADCs to more #patients. Learn what inspires Dr. Kanojia, below:?? ? #MeetMythic?

Tune in to the latest episode of The Chain, where host Nimish Gera, our Vice President of Biologics, speaks with Tariq Ghayur, Entrepreneur in Residence at FairJourney Biologics, about the cutting-edge work being done in bispecifics and #ADCs, the transformative role of #AI in pharmaceuticals and emerging trends that may shape the #biopharma industry in the coming years.??? ??? Listen to the full podcast here: https://bit.ly/3MJQiQ5?

Today,?on World Cancer Research Day,?Mythic honors the countless individuals battling cancer and their loved ones who walk beside them.?We understand that every day is a fight,?and even small steps can make a tremendous difference.? ? Our work at Mythic is driven by the hope that we can contribute to a future where cancer is not a life-threatening illness.?We stand in solidarity with patients,?caregivers,?and researchers around the globe,?united in the unwavering pursuit?of a cure.?? ? Together,?let's?embrace the power of innovation to drive change and create a future where cancer is no longer?a threat.? ? #WorldCancerResearchDay #ADCs?#CancerResearch

Traditional #ADCs often face challenges when trafficked as intact complexes, leading to target destruction and inefficient recycling. Engineered by our proprietary FateControl? platform, Mythic’s ADCs are designed for more effective internalization by target tissues, ensuring that a greater portion of each dose is delivered to its intended site.? Our novel approach has the potential to deliver more effective and safer treatments, optimizing health outcomes for #patients. Learn how we are setting new standards in ADC therapeutics, below and here: https://bit.ly/3XlcTss? ? #MythicMasterclass?

How has the new FDA guidance on #ProjectOptimus impacted #clinicaltrials in our industry? Our Chief Development Officer, Gilles Gallant, BPharm PhD FOPQ will be joining industry experts for an insightful webinar discussion on the transformative impact of Project Optimus on early-phase #oncology drug development. Register for the event and learn more, here: https://bit.ly/4e1uFX1?

Headed to #Boston next week? Join our Vice President, Technical Operations, Benjamin Hutchins, Ph.D., for a roundtable discussion exploring the standardized general control strategy for #ADCs and strategies for optimizing cost and efficiency in process development. Don’t miss this opportunity to gain valuable insights for maximizing effective impurity removal and #regulatory approval. Learn more: https://bit.ly/3XnRTBp